Mark Stejbach - Net Worth and Insider Trading
Mark Stejbach Net Worth
The estimated net worth of Mark Stejbach is at least $1 Million dollars as of 2024-04-24. Mark Stejbach is the SVP/Chief Comm Off, Alks Inc of Alkermes PLC and owns about 46,129 shares of Alkermes PLC (ALKS) stock worth over $1 Million. Mark Stejbach is also the Director of Flexion Therapeutics Inc and owns about 3,631 shares of Flexion Therapeutics Inc (FLXN) stock worth over $33,115. Details can be seen in Mark Stejbach's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Stejbach has not made any transactions after 2020-05-26 and currently still holds the listed stock(s).
Transaction Summary of Mark Stejbach
Mark Stejbach Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Stejbach owns 3 companies in total, including Flexion Therapeutics Inc (FLXN) , Alkermes PLC (ALKS) , and Tengion Inc (TNGNQ) .
Click here to see the complete history of Mark Stejbach’s form 4 insider trades.
Insider Ownership Summary of Mark Stejbach
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| FLXN | Flexion Therapeutics Inc | 2020-06-10 | director |
| ALKS | Alkermes PLC | 2018-02-16 | Chief Commercial Officer |
| TNGNQ | Tengion Inc | 2011-05-11 | VP and Chief Commercial Offcr |
Mark Stejbach Latest Holdings Summary
Mark Stejbach currently owns a total of 2 stocks. Among these stocks, Mark Stejbach owns 46,129 shares of Alkermes PLC (ALKS) as of February 16, 2018, with a value of $1 Million and a weighting of 97.13%. Mark Stejbach also owns 3,631 shares of Flexion Therapeutics Inc (FLXN) as of May 26, 2020, with a value of $33,115 and a weighting of 2.87%.
Latest Holdings of Mark Stejbach
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALKS | Alkermes PLC | 2018-02-16 | 46,129 | 24.26 | 1,119,090 |
| FLXN | Flexion Therapeutics Inc | 2020-05-26 | 3,631 | 9.12 | 33,115 |
Holding Weightings of Mark Stejbach
Mark Stejbach Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Stejbach has made a total of 0 transactions in Alkermes PLC (ALKS) over the past 5 years. The most-recent trade in Alkermes PLC is the sale of 10,880 shares on February 16, 2018, which brought Mark Stejbach around $767,040.
According to the SEC Form 4 filings, Mark Stejbach has made a total of 1 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Flexion Therapeutics Inc is the acquisition of 2,051 shares on May 26, 2020, which cost Mark Stejbach around $19,997.
Insider Trading History of Mark Stejbach
- 1
Mark Stejbach Trading Performance
GuruFocus tracks the stock performance after each of Mark Stejbach's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Stejbach is 27.39%. GuruFocus also compares Mark Stejbach's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Stejbach within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Stejbach's insider trading performs compared to the benchmark.
Performance of Mark Stejbach
Average Return
19.42%
Outperforming Transactions
50%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 33.89 | 27.39 | 29.25 | 19.42 | -20.48 | -10.69 |
| Relative Return to S&P 500(%) | 33.07 | 17.87 | 13.61 | -7.83 | -29.43 | -19.38 |
Mark Stejbach Ownership Network
Ownership Network List of Mark Stejbach
Ownership Network Relation of Mark Stejbach
Mark Stejbach Owned Company Details
What does Flexion Therapeutics Inc do?
Who are the key executives at Flexion Therapeutics Inc?
Mark Stejbach is the director of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Regulatory Officer Kerry Wentworth , General Counsel Mark S. Levine , and Chief Strategy Officer Christina Willwerth .
Flexion Therapeutics Inc (FLXN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Flexion Therapeutics Inc Insider Transactions
Mark Stejbach Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Stejbach. You might contact Mark Stejbach via mailing address: C/o Tengion, Inc., 2900 Potshop Lane, Suite 100, East Norriton Pa 19403.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
